Moderna. has been granted a patent for methods and compositions aimed at inducing a broad neutralizing antibody response against HIV. The approach involves administering mRNA formulations encoding HIV envelope and lentivirus Gag proteins, delivered in lipid nanoparticles, to elicit an immune response in subjects. GlobalData’s report on Moderna gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. Moderna's grant share as of July 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Inducing immune response against hiv using mrna compositions
The patent US12070495B2 outlines a method for inducing an immune response to human immunodeficiency virus (HIV) through a two-phase administration of messenger RNA (mRNA) compositions. The first phase involves administering an initial dose followed by multiple autologous boost doses of a composition containing mRNA encoding HIV envelope (Env) and lentivirus group-specific antigen (Gag) proteins, both formulated in lipid nanoparticles. The second phase consists of multiple heterologous boost doses of a different mRNA composition, also encoding HIV Env and Gag proteins. The goal of this method is to elicit a broadly neutralizing antibody response against various strains of HIV, specifically targeting shared epitopes on the viral proteins.
The claims further detail specific parameters of the method, including the timing and dosage of the mRNA compositions, the types of HIV targeted (primarily HIV type-1), and the ratios of the mRNA components. Additional claims specify the inclusion of mRNA encoding other proteins, such as HIV protease and furin, and outline various mutations and structural characteristics of the HIV Env proteins used in the compositions. The patent emphasizes the potential for these mRNA formulations to produce a robust immune response, characterized by high ID50 titers of neutralizing antibodies, which could enhance the effectiveness of HIV vaccines and therapies.
To know more about GlobalData’s detailed insights on Moderna, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
